TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Known CAH due to 21-hydroxylase deficiency (classic CAH) based on hormonal and genetic testing currently treated with hydrocortisone, prednisone, prednisolone or dexamethasone on a stable dosage for a minimum of 3 months.~2. Male or female patients aged 18 and above.~3. Provision of signed written informed consent.~4. Good general health.~5. Females of childbearing potential must have a negative pregnancy test initially and at all visits. Females who are engaging in sexual intercourse must be using a medically acceptable method of contraception (as defined in the protocol, section 10.5).~6. Plasma renin activity must be within the clinically acceptable range at screening (less than 1.5 times upper normal range).~Exclusion Criteria:~1. Co-morbid condition requiring daily administration of a medication that induces hepatic enzymes or interferes with the metabolism of glucocorticoids.~2. Clinical or biochemical evidence of hepatic or renal disease. Creatinine above the normal range or elevated liver function tests (ALT or AST) \> 2 times the upper limits of normal.~3. Females who are pregnant or lactating.~4. Women taking an estrogen-containing oral contraceptive pill and who have taken it within 6 weeks of recruitment.~5. Patients taking spironolactone.~6. Patients on inhaled or oral steroids apart from treatment for CAH.~7. Patients with any other significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the trial.~8. Participation in another clinical trial of an investigational or licensed drug or device within the 3 months prior to inclusion in this study.~9. Patients with history of bilateral adrenalectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydrocortisone Modified Release Capsules (Type: EXPERIMENTAL): Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism, and who consent to participate in the study.~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Pathologically confirmed diagnosis of Stage IIIB (with cytologically proven pleural effusion or pericardial effusion) or Stage IV adenocarcinoma of the lung. Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.~* Epidermal Growth Factor Receptor mutation detected by central laboratory analysis of tumour biopsy material.~* Measurable disease according to RECIST 1.1.~* Eastern Cooperative Oncology Group score of 0 or 1.~* Age \>/= 18 years.~* Life expectancy of at least three months.~* Written informed consent that is consistent with International Conference on Harmonisation-Good Clinical Practice guidelines.~Exclusion criteria:~* Prior chemotherapy for relapsed and/or metastatic NSCLC. Neoadjuvant/adjuvant chemotherapy is permitted if at least 12 months has elapsed between the end of chemotherapy and randomisation.~* Prior treatment with Epidermal Growth Factor Receptor targeting small molecules or antibodies.~* Radiotherapy or surgery (other than biopsy) within 4 weeks prior to randomisation.~* Active brain metastases~* Any other current malignancy or malignancy diagnosed within the past five years~* Known pre-existing interstitial lung disease.~* Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom.~* History or presence of clinically relevant cardiovascular abnormalities.~* Any other concomitant serious illness or organ system dysfunction.~* Adequate absolute neutrophil count and platelet count~* Adequate liver and kidney function~* Active hepatitis B infection, active hepatitis C infection or known HIV carrier.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBW 2992 (Type: EXPERIMENTAL): BIBW 2992 tablet once daily until progression
- Cisplatin/Pemetrexed (Type: ACTIVE_COMPARATOR): Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has completed the full dosing period in Protocol 137-150.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pramlintide Acetate (Type: ACTIVE_COMPARATOR): Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Participants with 'moderate' or 'severe' glabellar frown lines at maximum frown at the beginning of each treatment cycle (as assessed by the investigator according to FWS) , stable medical condition; Completion of one former study in the Merz NT 201 glabellar program~Exclusion Criteria:~Participants with preexisting neuromuscular diseases (e.g. myasthenia gravis, Lambert-Eaton syndrome) putting the participant at risk, History of Facial Nerve Palsy, Previous treatment with Botulinum Toxin in the glabellar area during the last 12 months, Previous treatment with biodegradable fillers or other procedures (e.g. chemical peeling, photo rejuvenation) in the glabellar area during the last 12 months, Previous insertion of permanent material in the glabellar area; Planned treatment with Botulinum toxin of any serotype in any body region during the study period, Any other planned facial aesthetic procedure in the glabellar area during the trial period; Any surgery in the glabellar area including surgical removal of the corrugator, procerus or depressor supercili muscles or a combination of these or scars in the glabellar area, Inability to substantially lessen glabellar frown lines even by physically spreading apart, Marked facial asymmetry or ptosis of eyelid and/or eyebrow; Any infection in the area of the injection sites.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin) (20 units) (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven, previously untreated Hodgkin's disease Stage IV OR Stage II or stage III with B symptoms (at least 1 of the following: unexplained weight loss greater than 10%, unexplained recurrent fever greater than 39 degrees C, or drenching night sweats) AND bulk disease (defined as a mediastinal mass greater than 1/3 of mediastinal thoracic diameter and/or nodal aggregate greater than 10.0 cm) The following cellular types are eligible: Mixed cellularity, not otherwise specified (NOS) Lymphocytic depletion, NOS Lymphocytic depletion, diffuse fibrosis Lymphocytic depletion, reticular Lymphocytic predominance, NOS Lymphocytic predominance, diffuse Lymphocytic predominance, nodular Hodgkin's paragranuloma Hodgkin's granuloma Hodgkin's sarcoma Nodular sclerosis, NOS Nodular sclerosis, cellular phase Nodular sclerosis, lymphocytic predominance Nodular sclerosis, mixed cellularity Nodular sclerosis, lymphocytic depletion Hodgkin's disease, NOS Must begin protocol therapy within 42 days of biopsy and 7 days of completion of staging~PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: No prior treatment for Hodgkin's disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- BEACOPP therapy (Type: EXPERIMENTAL): Patients receive 4 cycles of BEACOPP therapy. Drugs utilized in this regimen include Bleomycin (B), Etoposide (E), Doxorubicin (A), Cyclophosphamide (C), Vincristine (O), Prednisone (P) and Procarbazine (P). Each cycle lasts 21 days and is characterized by intravenous pulses of Etoposide (Days 0-2), Doxorubicin (Day 0), Cyclophosphamide (Day 0), Bleomycin (Day 7), Vincristine (Day 7). Seven days of oral procarbazine (Days 0-6) and 14 days of oral prednisone (Days 0-13) are given during each cycle.~Growth factor support with Filgrastim (G-CSF) is given by subcutaneous injection daily beginning Day 8. Response will then be determined and stratification for further treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient presenting with known or suspected enhancing abnormality(ies) and/or lesion(s) in at least one body region based on a previous imaging procedure performed within 12 months prior to ICF signature. US patients are restricted to the breast in compliance with local approved indications of gadobutrol.~Exclusion Criteria:~* Patient presenting with acute or chronic renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73 m² assessed within 1 day prior to each contrast agent administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI (Type: EXPERIMENTAL): Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI
- gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI (Type: EXPERIMENTAL): Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent~* Willing to participate,~* Women age 18 years and above~* Pregnant~* Untreated HIV infection in late pregnancy at ≥28 - 36 weeks gestation~Exclusion Criteria:~* Received antiretroviral drugs in previous 6 months~* Ever received integrase inhibitors~* Serum haemoglobin \< 8.0 g/dl~* Elevations in serum levels of alanine aminotransferase (ALT) \>5 times the upper limit of normal (ULN) or ALT \>3xULN and bilirubin \>2xULN (with \>35% direct bilirubin)~* eGFR \< 50ml/min~* Active Hepatitis B infection, history or clinical suspicion of unstable liver disease, or subjects with severe liver disease (Class C by Childs-Hugh criteria)~* Severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or liver abnormalities (e.g. grade 2 or above proteinuria, elevation in serum creatinine (above 2.5 x ULN), total bilirubin ALT or AST)~* Paternal non-consent (where disclosure to male partner has been made)~* Clinical depression or clinical judgement suggests increased risk of suicidality

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dolutegravir 50mg od (Type: EXPERIMENTAL): 30 patients who will receive dolutegravir 50mg once daily plus the same NRTI backbone as the active comparator group (lamivudine and tenofovir)
- Standard of Care (Type: ACTIVE_COMPARATOR): Patients randomised to receive antiretroviral therapy as per Uganda national guidelines (Efavirenz 600mg od based plus Tenofovir 300mg od and Lamivudine 300mg od)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Written Informed Consent~* Subjects with chronic phase chronic myeloid leukemia (CML)~* Subjects resistant/intolerant to imatinib~* Subjects presenting:~  1. ECOG performance status (PS) score 0-2~ 2. Adequate hepatic function~ 3. Adequate renal function~ 4. Adequate lung function~Exclusion Criteria:~* Concurrent malignancy other than CML~* Women who are pregnant or breastfeeding~* Concurrent pleural effusion~* Uncontrolled or significant cardiovascular disease~* A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy.~* Prior therapy with dasatinib~* Subjects with T315I and/or F317L BCR-ABL point mutations

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dasatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient is admitted to the trauma service.~* The patient has a hemothorax and/or or hemopneumothorax, requiring thoracostomy tube placement.~* Thoracostomy tube placement is able to be performed or witnessed by an investigator listed on the study.~* The patient has not had a chest tube in the past year.~* The patient is \>18 years of age.~* In the event the patient is decisionally impaired, consent will be obtained from the individual's legally authorized representative (LAR) or from the individual's healthcare power of attorney (HPA).~* In the instance of reversible impairment, initial consent would be obtained from the LAR/HPA and the patient will be approached for consent once he/she is deemed mentally competent by the care provider.~Exclusion Criteria:~* The patient is incarcerated~* The patient is known to be pregnant~* The patient is \< 18 years of age~* The patient is hemodynamically unstable, requiring emergent chest tube placement (in \<10 minutes from evaluation).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 28 French chest tube for hemothorax (Type: EXPERIMENTAL): 28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
- 14 French chest tube for hemothorax (Type: EXPERIMENTAL): 14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lumbar Plexus vs Quadratus Lumborum Block in Post-operative Pain Following Total Hip Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18-90 years old~2. Primary unilateral total hip arthroplasty~3. BMI 20 - 36~4. Male and Female~5. All races~Exclusion Criteria:~1. Patient refusal~2. ASA class \> or = 4~3. Pregnancy~4. Any condition precluding patient going home with in 24 hours of surgery~5. Non-English speaking or inability to participate in the study~6. Patients with coagulopathy or on therapeutic anticoagulation~7. Chronic Steroid Use~8. Narcotic Addiction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Lumbar Plexus block (Type: ACTIVE_COMPARATOR): 0.5% ropivacaine 100 mg (20 ml) will be injected
- Quadratus Lumborum type 3 block (Type: EXPERIMENTAL): 0.5% ropivacaine 100 mg (20 ml) will be injected

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed metastatic (stage IV) NSCLC with no significant pleural effusion or pleural involvement from the tumor~* Age greater than or equal to 18 years~* Adequate organ and bone marrow function~Exclusion Criteria:~* Any prior systemic therapy for NSCLC~* Major surgical procedure or other investigational agents within 4 weeks before study enrollment~* Need for concomitant use of other thiazolidinediones during the study~* History of any of the following conditions within 6 months prior to initiating study treatment: Diabetes mellitus requiring treatment with insulin or sulfonylureas or thiazolidinediones (TZDs) agents; Myocardia infarction with significant impairment of cardia function; Malabsorption syndrome, chronic diarrhea, inflammatory bowel disease or partial bowel obstruction;~* Clinically active brain metastases, uncontrolled seizure disorder; spinal cord compression or carcinomatous meningitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CS-7017 with Paclitaxel and Carboplatin (Type: EXPERIMENTAL): None
- Paclitaxel and Carboplatin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients between 18 years and 80 years.~2. Patients having moderate to severe IBD according to European Crohn's and colitis organization (ECCO) guidelines.~3. IBD patients receiving either IFX or ADA.~Exclusion Criteria:~1. Patients missed one-year follow-up or with missed data.~2. Patients having mild IBD according to ECCO guidelines.~3. Patients having any of the Contraindications to the biological Therapy e.g.: latent TB, viral or fungal or bacterial infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Infliximab. (Type: ACTIVE_COMPARATOR): group 1 (n=20): patients will receive IFX,
- Adalimumab. (Type: ACTIVE_COMPARATOR): group 2 (n=20): patients will receive ADA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete